Research programme: ROR-c inhibitors - Biolexis Therapeutics
Latest Information Update: 06 Nov 2023
At a glance
- Originator Biolexis Therapeutics
- Class Small molecules
- Mechanism of Action Retinoic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 11 Oct 2023 ROR-c inhibitors are available for licensing as of 11 Oct 2023. https://biolexistx.com/pipeline/ (Biolexis Therapeutics pipeline, October 2023)
- 11 Oct 2023 Early research in Unspecified in USA (unspecified route), before October 2023 (Biolexis Therapeutics pipeline, October 2023)